Analyze Diet
Equine veterinary journal. Supplement1989; (7); 111-116; doi: 10.1111/j.2042-3306.1989.tb05668.x

Comparison of detomidine, butorphanol, flunixin meglumine and xylazine in clinical cases of equine colic.

Abstract: Detomidine hydrochloride, butorphanol tartrate, flunixin meglumine and xylazine hydrochloride were evaluated in a blind multi-centre clinical trial in 152 horses with abdominal pain. The drugs were administered as follows: detomidine 20 or 40 micrograms/kg bodyweight (bwt); butorphanol 0.1 mg/kg bwt; flunixin meglumine 1.0 mg/kg bwt; xylazine hydrochloride 0.5 mg/kg bwt. Each centre compared responses to the two doses of detomidine with those to one of the other analgesics. The drugs were administered intravenously (i.v.) after clinical assessment of the degree of sweating, kicking, pawing, head and body movement, attitude, lip curling, stretching to urinate, pulse rate, respiratory rate and rectal temperature. Similar assessments were repeated at 15 min intervals for at least 1 h. The investigators ranked the response to treatment from 'not satisfactory' to 'highly satisfactory'. Significant differences in sweating, kicking, pawing, head and body movement, attitude, pulse rate and respiratory rate were noted between the horses receiving butorphanol and either dose of detomidine. The investigators' subjective evaluation of the analgesic and sedative effects of either dose of detomidine were significantly better than for butorphanol. Analgesia was rated as highly satisfactory or satisfactory in 93.3 per cent and 6.7 per cent of the horses receiving 40 micrograms/kg bwt of detomidine, 73.3 per cent and 26.7 per cent of the horses receiving 20 micrograms/kg bwt of detomidine, and none of the horses receiving butorphanol. There were no differences in the incidence of side effects with the two compounds. Significant differences were noted in kicking, pawing, head and body movement and attitude between the horses receiving flunixin meglumine and either dose of detomidine. Flunixin meglumine provided significantly less analgesia than either dose of detomidine. Analgesia was rated as highly satisfactory or satisfactory in 73.7 per cent and 21.0 per cent of the horses receiving 40 micrograms/kg bwt of detomidine, 42.9 per cent and 21.4 per cent of the horses receiving 20 micrograms/kg bwt of detomidine, and 6.3 per cent and 37.5 per cent of the horses receiving xylazine. Sedation was considered to be at least satisfactory in 84.2 per cent of the horses receiving 40 micrograms/kg of detomidine, 71.5 per cent of the horses receiving 20 micrograms/kg of detomidine and 53.3 per cent of the horses receiving xylazine.
Publication Date: 1989-06-01 PubMed ID: 9118091DOI: 10.1111/j.2042-3306.1989.tb05668.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Clinical Trial
  • Comparative Study
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the effectiveness of four different drugs – detomidine, butorphanol, flunixin meglumine and xylazine – in treating abdominal pain in horses. The results revealed that detomidine at both 20 and 40 micrograms/kg body weight provided the most effective pain relief, with significantly less effectiveness observed for butorphanol and flunixin meglumine.

Methodology and Objectives

  • The research was a blind, multi-centre clinical trial involving 152 horses suffering from abdominal pain.
  • The four drugs under consideration were administrated intravenously at different concentrations relative to the body weight of the horse.
  • A series of clinical assessments were made both prior to and following drug administration.
  • The drugs’ analgesic and sedative effects were evaluated and ranked by investigators based on the observed symptoms such as sweating, kicking, pawing, pulse and respiratory rate.

Findings and Conclusions

  • Significant reduction in symptoms were observed in horses receiving either dose of detomidine compared to those receiving butorphanol.
  • Both detomidine dosages resulted in more effective pain relief (analgesia) than butorphanol, as reported in the improvement percentages (93.3% and 73.3% vs none).
  • There was no significant difference in the occurrence of side effects between butorphanol and detomidine.
  • Similarly, flunixin meglumine also provided less analgesia compared to both doses of detomidine.
  • Xylazine resulted in satisfactory sedation in approximately 53.3% of horses, lower than the 84.2% and 71.5% in horses receiving 40 and 20 micrograms/kg bwt of detomidine respectively.
  • The data suggests that detomidine, at both tested dosages, is more effective than butorphanol, flunixin meglumine, and xylazine in treating equine colic symptoms and providing sufficient sedation.

Cite This Article

APA
Jochle W, Moore JN, Brown J, Baker GJ, Lowe JE, Fubini S, Reeves MJ, Watkins JP, White NA. (1989). Comparison of detomidine, butorphanol, flunixin meglumine and xylazine in clinical cases of equine colic. Equine Vet J Suppl(7), 111-116. https://doi.org/10.1111/j.2042-3306.1989.tb05668.x

Publication

NlmUniqueID: 9614088
Country: United States
Language: English
Issue: 7
Pages: 111-116

Researcher Affiliations

Jochle, W
  • Wolfgang Jochle Associates Inc, Denville, New Jersey 07834, USA.
Moore, J N
    Brown, J
      Baker, G J
        Lowe, J E
          Fubini, S
            Reeves, M J
              Watkins, J P
                White, N A

                  MeSH Terms

                  • Adrenergic alpha-Agonists / adverse effects
                  • Adrenergic alpha-Agonists / pharmacology
                  • Adrenergic alpha-Agonists / therapeutic use
                  • Analgesics / administration & dosage
                  • Analgesics / pharmacology
                  • Analgesics / therapeutic use
                  • Analgesics, Opioid / adverse effects
                  • Analgesics, Opioid / pharmacology
                  • Analgesics, Opioid / therapeutic use
                  • Animals
                  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
                  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
                  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
                  • Behavior, Animal / drug effects
                  • Behavior, Animal / physiology
                  • Butorphanol / administration & dosage
                  • Butorphanol / pharmacology
                  • Butorphanol / therapeutic use
                  • Clonixin / administration & dosage
                  • Clonixin / analogs & derivatives
                  • Clonixin / pharmacology
                  • Clonixin / therapeutic use
                  • Colic / drug therapy
                  • Colic / physiopathology
                  • Colic / veterinary
                  • Dose-Response Relationship, Drug
                  • Double-Blind Method
                  • Heart Rate / drug effects
                  • Heart Rate / physiology
                  • Horse Diseases / drug therapy
                  • Horse Diseases / physiopathology
                  • Horses
                  • Hypnotics and Sedatives / administration & dosage
                  • Hypnotics and Sedatives / pharmacology
                  • Hypnotics and Sedatives / therapeutic use
                  • Imidazoles / administration & dosage
                  • Imidazoles / pharmacology
                  • Imidazoles / therapeutic use
                  • Injections, Intravenous
                  • Respiration / drug effects
                  • Respiration / physiology
                  • Time Factors
                  • Xylazine / administration & dosage
                  • Xylazine / pharmacology
                  • Xylazine / therapeutic use